{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:27Z","timestamp":1793747067598,"version":"4.6.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["PF-20-106-01-LIB"],"award-info":[{"award-number":["PF-20-106-01-LIB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["Fellowship Program"],"award-info":[{"award-number":["Fellowship Program"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA206890"],"award-info":[{"award-number":["R01CA206890"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA079443"],"award-info":[{"award-number":["T32CA079443"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA206997"],"award-info":[{"award-number":["U01CA206997"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA112967"],"award-info":[{"award-number":["U54CA112967"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA217377"],"award-info":[{"award-number":["U54CA217377"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R00CA207744"],"award-info":[{"award-number":["R00CA207744"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["DP2CA259675"],"award-info":[{"award-number":["DP2CA259675"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL131495"],"award-info":[{"award-number":["R01HL131495"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41565-021-00897-1","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T12:03:37Z","timestamp":1620302617000},"page":"830-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Ran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S. C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Prytyskach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-0802","authenticated-orcid":false,"given":"Christopher B.","family":"Rodell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-9722","authenticated-orcid":false,"given":"Hannes","family":"Mikula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6269-6590","authenticated-orcid":false,"given":"Rainer H.","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Garlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-989X","authenticated-orcid":false,"given":"Douglas A.","family":"Lauffenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh","family":"Parangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M.","family":"Dinulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Bardeesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-4143","authenticated-orcid":false,"given":"Ralph","family":"Weissleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-8898","authenticated-orcid":false,"given":"Miles A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"897_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nm.4256","volume":"23","author":"SM Davidson","year":"2017","unstructured":"Davidson, S. M. et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat. Med. 23, 235\u2013241 (2017).","journal-title":"Nat. Med."},{"key":"897_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","volume":"497","author":"C Commisso","year":"2013","unstructured":"Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633\u2013637 (2013).","journal-title":"Nature"},{"key":"897_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.devcel.2019.05.043","volume":"50","author":"SW Lee","year":"2019","unstructured":"Lee, S. W. et al. EGFR-Pak signaling selectively regulates glutamine deprivation-induced macropinocytosis. Dev. Cell 50, 381\u2013392.e5 (2019).","journal-title":"Dev. Cell"},{"key":"897_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1062-1","volume":"568","author":"W Yao","year":"2019","unstructured":"Yao, W. et al. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature 568, 410\u2013414 (2019).","journal-title":"Nature"},{"key":"897_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A. nab-Paclitaxel mechanisms of action and delivery. J. Control. Release 170, 365\u2013372 (2013).","journal-title":"J. Control. Release"},{"key":"897_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","volume":"130","author":"EN Hoogenboezem","year":"2018","unstructured":"Hoogenboezem, E. N. & Duvall, C. L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 130, 73\u201389 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"897_CR7","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/nnm-2018-0313","volume":"14","author":"MA Barkat","year":"2019","unstructured":"Barkat, M. A., Beg, S., Pottoo, F. H. & Ahmad, F. J. Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. Nanomed. 14, 1323\u20131341 (2019).","journal-title":"Nanomed."},{"key":"897_CR8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1208\/s12248-016-9970-6","volume":"18","author":"HA Havel","year":"2016","unstructured":"Havel, H. A. Where are the nanodrugs? An industry perspective on development of drug products containing nanomaterials. AAPS J. 18, 1351\u20131353 (2016).","journal-title":"AAPS J."},{"key":"897_CR9","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski, M. A. et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J. Clin. Oncol. 30, 2055\u20132062 (2012).","journal-title":"J. Clin. Oncol."},{"key":"897_CR10","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J. Clin. Oncol. 29, 4548\u20134554 (2011).","journal-title":"J. Clin. Oncol."},{"key":"897_CR11","doi-asserted-by":"crossref","unstructured":"Waters, A. M. & Der, C. J. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect. Med. 8, a031435 (2018).","DOI":"10.1101\/cshperspect.a031435"},{"key":"897_CR12","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1200\/JCO.2019.37.15_suppl.4000","volume":"37:15","author":"MA Tempero","year":"2019","unstructured":"Tempero, M. A. et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P\/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J. Clin. Oncol. 37:15, 4000 (2019).","journal-title":"J. Clin. Oncol."},{"key":"897_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1593\/tlo.09109","volume":"2","author":"N Desai","year":"2009","unstructured":"Desai, N., Trieu, V., Damascelli, B. & Soon-Shiong, P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2, 59\u201364 (2009).","journal-title":"Transl. Oncol."},{"key":"897_CR14","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1158\/1078-0432.CCR-14-3222","volume":"21","author":"M Hidalgo","year":"2015","unstructured":"Hidalgo, M. et al. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin. Cancer Res. 21, 4811\u20134818 (2015).","journal-title":"Clin. Cancer Res."},{"key":"897_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/gutjnl-2013-305559","volume":"63","author":"A Neesse","year":"2014","unstructured":"Neesse, A. et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 63, 974\u2013983 (2014).","journal-title":"Gut"},{"key":"897_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2326-6066.CIR-16-0125","volume":"5","author":"J Cullis","year":"2017","unstructured":"Cullis, J. et al. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol. Res. 5, 182\u2013190 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"897_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.2972","volume":"11","author":"G Lukinavi\u010dius","year":"2014","unstructured":"Lukinavi\u010dius, G. et al. Fluorogenic probes for live-cell imaging of the cytoskeleton. Nat. Methods 11, 731\u2013733 (2014).","journal-title":"Nat. Methods"},{"key":"897_CR18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/nprot.2009.95","volume":"4","author":"M DuPage","year":"2009","unstructured":"DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064\u20131072 (2009).","journal-title":"Nat. Protoc."},{"key":"897_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14293","volume":"8","author":"MF Cuccarese","year":"2017","unstructured":"Cuccarese, M. F. et al. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. Nat. Commun. 8, 14293 (2017).","journal-title":"Nat. Commun."},{"key":"897_CR20","first-page":"1454","volume":"59","author":"A Sparreboom","year":"1999","unstructured":"Sparreboom, A. et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood. Cancer Res. 59, 1454\u20131457 (1999).","journal-title":"Cancer Res."},{"key":"897_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","volume":"19","author":"S Sindhwani","year":"2020","unstructured":"Sindhwani, S. et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566\u2013575 (2020).","journal-title":"Nat. Mater."},{"key":"897_CR22","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1021\/ja2084338","volume":"134","author":"CD Walkey","year":"2012","unstructured":"Walkey, C. D., Olsen, J. B., Guo, H., Emili, A. & Chan, W. C. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134, 2139\u20132147 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"897_CR23","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.cell.2014.04.039","volume":"157","author":"S Regot","year":"2014","unstructured":"Regot, S., Hughey, J. J., Bajar, B. T., Carrasco, S. & Covert, M. W. High-sensitivity measurements of multiple kinase activities in live single cells. Cell 157, 1724\u20131734 (2014).","journal-title":"Cell"},{"key":"897_CR24","doi-asserted-by":"publisher","first-page":"12015","DOI":"10.1021\/acsnano.8b04338","volume":"12","author":"HY Kim","year":"2018","unstructured":"Kim, H. Y. et al. Quantitative imaging of tumor-associated macrophages and their response to therapy using 64Cu-labeled macrin. ACS Nano 12, 12015\u201312029 (2018).","journal-title":"ACS Nano"},{"key":"897_CR25","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1158\/0008-5472.CAN-17-3199","volume":"78","author":"G Redelman-Sidi","year":"2018","unstructured":"Redelman-Sidi, G. et al. The canonical Wnt pathway drives macropinocytosis in cancer. Cancer Res. 78, 4658\u20134670 (2018).","journal-title":"Cancer Res."},{"key":"897_CR26","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2013.54.4932","volume":"32","author":"CJ Langer","year":"2014","unstructured":"Langer, C. J. et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 32, 2059\u20132066 (2014).","journal-title":"J. Clin. Oncol."},{"key":"897_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s43018-019-0007-9","volume":"1","author":"D Ajona","year":"2020","unstructured":"Ajona, D. et al. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nat. Cancer 1, 75\u201385 (2020).","journal-title":"Nat. Cancer"},{"key":"897_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrm3311","volume":"13","author":"DG Hardie","year":"2012","unstructured":"Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251\u2013262 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"897_CR29","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2159-8290.CD-17-1215","volume":"8","author":"SM Kim","year":"2018","unstructured":"Kim, S. M. et al. PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Disco. 8, 866\u2013883 (2018).","journal-title":"Cancer Disco."},{"key":"897_CR30","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1210\/en.2011-0155","volume":"152","author":"J Ning","year":"2011","unstructured":"Ning, J., Xi, G. & Clemmons, D. R. Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology 152, 3143\u20133154 (2011).","journal-title":"Endocrinology"},{"key":"897_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.domaniend.2007.03.001","volume":"34","author":"L Tosca","year":"2008","unstructured":"Tosca, L., Chabrolle, C., Crochet, S., Tesseraud, S. & Dupont, J. IGF-1 receptor signaling pathways and effects of AMPK activation on IGF-1-induced progesterone secretion in hen granulosa cells. Domest. Anim. Endocrinol. 34, 204\u2013216 (2008).","journal-title":"Domest. Anim. Endocrinol."},{"key":"897_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0051-4","volume":"2","author":"MC Wagle","year":"2018","unstructured":"Wagle, M. C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis Oncol. 2, 7 (2018).","journal-title":"NPJ Precis Oncol."},{"key":"897_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.molcel.2017.12.024","volume":"69","author":"L Wan","year":"2018","unstructured":"Wan, L. et al. Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Mol. Cell 69, 279\u2013291.e5 (2018).","journal-title":"Mol. Cell"},{"key":"897_CR34","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/adhm.201200467","volume":"2","author":"M Cui","year":"2013","unstructured":"Cui, M. et al. Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. Adv. Health. Mater. 2, 1236\u20131245 (2013).","journal-title":"Adv. Health. Mater."},{"key":"897_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1208\/s12248-014-9670-z","volume":"17","author":"JL Zaro","year":"2015","unstructured":"Zaro, J. L. Lipid-based drug carriers for prodrugs to enhance drug delivery. AAPS J. 17, 83\u201392 (2015).","journal-title":"AAPS J."},{"key":"897_CR36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","volume":"11","author":"MA Bush","year":"2009","unstructured":"Bush, M. A. et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes. Metab. 11, 498\u2013505 (2009).","journal-title":"Diabetes Obes. Metab."},{"key":"897_CR37","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1021\/acs.molpharmaceut.8b00806","volume":"15","author":"Z Suo","year":"2018","unstructured":"Suo, Z. et al. Investigation on the interaction of dabrafenib with human serum albumin using combined experiment and molecular dynamics simulation: exploring the binding mechanism, esterase-like activity, and antioxidant activity. Mol. Pharm. 15, 5637\u20135645 (2018).","journal-title":"Mol. Pharm."},{"key":"897_CR38","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","volume":"12","author":"M Scaltriti","year":"2006","unstructured":"Scaltriti, M. & Baselga, J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12, 5268\u20135272 (2006).","journal-title":"Clin. Cancer Res."},{"key":"897_CR39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656\u2013670 (2012).","journal-title":"Cell"},{"key":"897_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nm1173","volume":"11","author":"DM Dinulescu","year":"2005","unstructured":"Dinulescu, D. M. et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11, 63\u201370 (2005).","journal-title":"Nat. Med."},{"key":"897_CR41","doi-asserted-by":"publisher","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","volume":"109","author":"SM McAuliffe","year":"2012","unstructured":"McAuliffe, S. M. et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl Acad. Sci. USA 109, E2939\u2013E2948 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"897_CR42","doi-asserted-by":"publisher","first-page":"E1600","DOI":"10.1073\/pnas.1404357111","volume":"111","author":"DG McFadden","year":"2014","unstructured":"McFadden, D. G. et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc. Natl Acad. Sci. USA 111, E1600\u2013E1609 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"897_CR43","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.18632\/oncotarget.2130","volume":"5","author":"P Vanden Borre","year":"2014","unstructured":"Vanden Borre, P. et al. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget 5, 3996\u20134010 (2014).","journal-title":"Oncotarget"},{"key":"897_CR44","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell, C. B. et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578\u2013588 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"897_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/thy.2013.0483","volume":"24","author":"P Vanden Borre","year":"2014","unstructured":"Vanden Borre, P. et al. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid 24, 705\u2013714 (2014).","journal-title":"Thyroid"},{"key":"897_CR46","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/0008-5472.CAN-03-2522","volume":"64","author":"A Girnita","year":"2004","unstructured":"Girnita, A. et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64, 236\u2013242 (2004).","journal-title":"Cancer Res."},{"key":"897_CR47","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.4155\/fmc.09.89","volume":"1","author":"MJ Mulvihill","year":"2009","unstructured":"Mulvihill, M. J. et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153\u20131171 (2009).","journal-title":"Future Med. Chem."},{"key":"897_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9692","volume":"6","author":"MA Miller","year":"2015","unstructured":"Miller, M. A. et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat. Commun. 6, 8692 (2015).","journal-title":"Nat. Commun."},{"key":"897_CR49","doi-asserted-by":"publisher","first-page":"E11406","DOI":"10.1073\/pnas.1800047115","volume":"115","author":"JJ Pineda","year":"2018","unstructured":"Pineda, J. J. et al. Site occupancy calibration of taxane pharmacology in live cells and tissues. Proc. Natl Acad. Sci. USA 115, E11406\u2013E11414 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"897_CR50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/bc8004649","volume":"20","author":"NK Devaraj","year":"2009","unstructured":"Devaraj, N. K., Keliher, E. J., Thurber, G. M., Nahrendorf, M. & Weissleder, R. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem. 20, 397\u2013401 (2009).","journal-title":"Bioconjug Chem."},{"key":"897_CR51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1021\/bc980125h","volume":"10","author":"L Josephson","year":"1999","unstructured":"Josephson, L., Tung, C. H., Moore, A. & Weissleder, R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem. 10, 186\u2013191 (1999).","journal-title":"Bioconjug Chem."},{"key":"897_CR52","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0378-5173(03)00134-0","volume":"257","author":"K Langer","year":"2003","unstructured":"Langer, K. et al. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 257, 169\u2013180 (2003).","journal-title":"Int. J. Pharm."},{"key":"897_CR53","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijpharm.2007.06.028","volume":"347","author":"K Langer","year":"2008","unstructured":"Langer, K. et al. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. Int. J. Pharm. 347, 109\u2013117 (2008).","journal-title":"Int. J. Pharm."},{"key":"897_CR54","first-page":"1239","volume":"8","author":"M Tsubaki","year":"2018","unstructured":"Tsubaki, M. et al. Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1\/2 activation. Am. J. Cancer Res. 8, 1239\u20131248 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"897_CR55","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/blood-2005-01-0293","volume":"107","author":"E Menu","year":"2006","unstructured":"Menu, E. et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107, 655\u2013660 (2006).","journal-title":"Blood"},{"key":"897_CR56","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.intimp.2007.10.019","volume":"8","author":"W Xu","year":"2008","unstructured":"Xu, W., Tamura, T. & Takatsu, K. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway. Int. Immunopharmacol. 8, 351\u2013361 (2008).","journal-title":"Int. Immunopharmacol."},{"key":"897_CR57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"897_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1148\/radiol.2020201791","volume":"298","author":"TSC Ng","year":"2020","unstructured":"Ng, T. S. C. et al. Detecting immune response to therapies targeting PDL1 and BRAF using ferumoxytol MRI and Macrin in anaplastic thyroid cancer. Radiology 298, 123\u2013132 (2020).","journal-title":"Radiology"},{"key":"897_CR59","doi-asserted-by":"publisher","first-page":"314ra183","DOI":"10.1126\/scitranslmed.aac6522","volume":"7","author":"MA Miller","year":"2015","unstructured":"Miller, M. A. et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci. Transl. Med. 7, 314ra183 (2015).","journal-title":"Sci. Transl. Med."},{"key":"897_CR60","doi-asserted-by":"crossref","unstructured":"Miller, M. A. et al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci. Transl. Med. 9, eaal0225 (2017).","DOI":"10.1126\/scitranslmed.aal0225"}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41565-021-00897-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41565-021-00897-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41565-021-00897-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:00:35Z","timestamp":1684605635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-021-00897-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1038\/s41565-021-00897-1","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.W. is a cofounder of T2Biosystems and Lumicell, serves as a scientific adviser for ModeRNA Therapeutics, Tarveda Therapeutics and Alivio Therapeutics. None of these activities are related to the paper. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}